Genetic Counselor. Runner. Opinions are mine.
Joined February 2015
- Tweets554
- Following92
- Followers231
- Likes312
In a cohort at average risk for colorectal cancer, a cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions. Full ECLIPSE study results: nej.md/3v0J319
ALT Figure S1: Colorectal Cancer Sensi vity According to Stage at Diagnosis Pathology confirmed, incompletely staged cancers not shown (N = 7)
150
TFW your company debuts their new test in the New England Journal of Medicine!!! 👏👏👏👏 perfect timing during #ColorectalCancerAwarenessMonth
We are on our way to closing the #ColorectalCancer screening gap with our Shield blood test. Results of our 20,000-patient ECLIPSE study are now published in @NEJM, reinforcing the validity of the test.
Read more: investors.guardanthealth.com…
2
153
Worked for a health insurance provider, lab benefit manager, or guideline/tech assessment vendor in the past 2 years in a role related to policy, pharmacy, genomics, or one? Please consider taking my 8 minute survey by clicking this anonymous link below.
clemson.ca1.qualtrics.com/jf…
I made a 2024 Meetings Notebook/Planner to keep track of recurring meetings, conferences, and notes for sessions including pesky codes for continuing education! 😂 amazon.com/dp/B0CQG4PXLN?ref…
2
200
My colleague (and friend) is pretty darn impressive!
MSI-H as a biomarker has come so far from when I started in (germline) genetics clinic. Loved leading this work alongside an esteemed group of clinicians and publish ctDNA's reliable ability to rapidly identify patients who may benefit from IO. What's next?! Onward!! 🚀
1
1
187
Julie Wiedower retweeted
We know that #ComprehensiveMolecularGenotyping is essential in patients with advanced #NSCLC - but do we know if availability of results impacts #Survival?
In a real world cohort study, we asked this question
@MMarmarelis - out now in @JCOPO_ASCO @ASCO
👉🏽tinyurl.com/2mnbnsxw
An Illumina and Optum ASCO poster showed in payer claims data that 43% to 78% of patients with various advanced cancers did not receive ANY biomarker testing at all- despite a wealth of studies and guidelines supporting genomic profiling. Time to cover multi-cancer NGS panels?
1
2
280
The only #LabWeek2023 tweet I need
164
When I submit a 3 hour PTO request for this afternoon- I’m putting “Speak to Netflix.” In the memo line ….
1
251
Julie Wiedower retweeted
👇🏾What are the odds?
Metastatic #PancreasCancer with
#KRASG12C
➕
#BRCA2
Latter confirmed as germline as well.
💡In a perfect🌍with no limits, what would you do now and/or later?💭
#PANCSM #PrecisionMedicine @TumorBoardTues @OncoAlert @OncBrothers @Aiims1742 @PancPathologist – at Manhattan, NY
Julie Wiedower retweeted
BREAKING NEWS – The first-ever treatment for #Rettsyndrome, Trofinetide, has been approved by the FDA! Learn more about this historic announcement: rettsyndrome.org/trofinetide…
Julie Wiedower retweeted
🆕Published today🗞️
@ASCO #ASCODailyNews
“Utility & Debate of #LiquidBiopsies in Surveillance Setting”
The❓of what go do if someone is #ctDNA➕. My 2 cents👇🏾.
💡Adjuvant-Plus or #MRD-plus setting➡️🆕platform for trials.
@OncoAlert @DrawImpacts
Link: dailynews.ascopubs.org/do/ut… – at Balochistan, Pakistan
So helpful!
🔥Advances in antibody-based therapy in oncology
@NatureCancer
doi.org/10.1038/s43018-023-0…
👏Amazing review
😅what you always wanted to know about antibodies in oncology, here it is explained.. ADCC, ADCP, Fc engineering, BiTEs, RICs, IO combo, ADC...
@myESMO @OncoAlert @EASLedu
112
One thing I love about #genechat is that when new GCs talk ab an issue like challenges and delays in Board exam or results- I don’t see many “well we had it way worse” posts. I see empathy and advocacy on behalf of our colleagues. That’s just nice and I like it 🤗🤗🤗
1
20
1,034